Erasca, Inc. (ERAS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$15.70-3.56%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Manage IP litigation risk on ERAS-0015: IP challenge filed 2026-06-08; no resolution reported vs 4-quarter target.
Erasca is advancing its ERAS-0015 clinical trials despite challenges. The company aims to fund operations into the second half of 2028. Expert feedback on ERAS-0015 is encouraging. This supports potential future value from its oncology pipeline.
Erasca is loss-making with negative EPS expected through 2027. Litigation and IP challenges threaten its key asset ERAS-0015. Recent earnings missed expectations. These risks could delay or derail drug development.
The stock trades about 20% below our fair value of $23, in line with the Street median. The market prices in negative growth and ongoing losses. Our view differs by emphasizing the risk from litigation and cash runway.
Breaks if: Cash runway falls short of H2 2028 funding needs
Breaks if: Failure to meet mid-2026 Phase 1 data readout or dose escalation delays
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a speculative growth play. The current thesis is cautious due to recent weak financial performance and elevated risk, despite some positive sector momentum.
The market appears to have low expectations for ERAS, as it is currently loss-making and has not shown recent strength compared to its peers. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news at this moment.
Fundamentals are likely to remain weak in the near term, given the high probability of missing earnings expectations. Management is focused on funding operations through 2028 and advancing clinical trials, but recent changes suggest a decline in company momentum.
The long-term thesis hinges on several factors, including the potential for management to meet operational goals and the impact of broader healthcare sector performance. Key triggers include guidance updates and the performance of sector bellwethers.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company is experiencing a sharp drop in price. This decline suggests the market is repricing the reasons to own it. Recent financial performance remains below its industry peers, which is concerning.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Progress clinical development of ERAS-0015 including monotherapy expansion and combination dose escalation cohorts with data readouts planned in H1 2027.
Newly stated in 2026-Q1. Management reported advancing ERAS-0015 clinical development ahead of schedule with monotherapy expansion and combination dose escalation cohorts initiated ahead of original guidance. No financial metrics directly tied to this priority are available, but clinical milestones are progressing as stated.
“We continue to execute well across our RAS-targeting franchise, advancing ERAS-0015 clinical development ahead of schedule.”
Breaks if: Unfavorable IP rulings that halt ERAS-0015 development
Over the next 1 to 3 years, ERAS will need to navigate significant risks while leveraging sector trends for potential recovery. Not investment advice.